ArticleDrug design, development and therapy2026
β-Amyrin Acetate Confers Anti-Epileptic Protection via Suppression of Calcium Overload-Induced Neuroinflammation and Apoptosis.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: β-Amyrin acetate (BAA), a natural pentacyclic triterpenoid, exhibits greater lipophilicity than its antiepileptic precursor β-amyrin, implying enhanced blood-brain barrier (BBB) permeability. This study aimed to evaluate the antiepileptic efficacy of BAA and investigate its neuroprotective mechanisms, with a focus on calcium signaling. Patients and Methods: An epilepsy model was established in zebrafish using pentylenetetrazole (PTZ) to assess the effects of BAA on seizure-like behaviors, reactive oxygen species (ROS) levels, apoptosis, and inflammatory markers. Potential targets were predicted via network pharmacology and molecular docking. Furthermore, a glutamate (Glu)-induced HT-22 neuronal injury model was used to validate BAA's effects on intracellular calcium homeostasis and downstream signaling pathways. Results: BAA significantly attenuated PTZ-induced seizure-like behaviors in zebrafish, specifically reducing the frequency of clonic and tonic-clonic seizures, as well as total movement distance and velocity. Concurrently, BAA mitigated oxidative stress, apoptosis, and neuroinflammation in the zebrafish. Network pharmacology and molecular docking analyses suggested the calcium signaling pathway as a potential target, with BAA showing high binding affinity to proteins such as Bcl-2 and JAK2. In vitro experiments suggested that BAA effectively alleviated Glu-induced calcium overload in HT-22 cells. It downregulated the Bax/Bcl-2 ratio, suppressed overactivation of the JAK2/STAT3 pathway, and consequently reduced neuronal apoptosis and inflammation. The BAPTA-AM co-treatment experiment further supported that the protective effect of BAA depends on the regulation of intracellular calcium homeostasis. Conclusion: BAA exerts antiepileptic effects by inhibiting neuronal calcium overload and modulating the JAK2/STAT3 signaling pathway, thereby attenuating neuroinflammation and apoptosis. These findings provide a solid experimental foundation for developing BAA as a promising antiepileptic candidate and elucidate its multi-target mechanism of action.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.